$10.9m to Siteman Cancer Center Targeting Deadly Pancreatic Cancer—3 Clinical Trials

Researchers at Washington University School of Medicine in St. Louis have received a prestigious Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to support research and clinical trials aimed at improving therapies for pancreatic cancer. Worth $10.9 million for research ongoing for five years, this aids in the development of novel therapies targeting pancreatic ductal adenocarcinoma, the deadliest form of pancreatic cancer. Fewer than 10% of patients with this cancer survive longer than five years after diagnosis.

The study effort for SPORE is co-led by David G. DeNardo, Ph.D., a professor of medicine, Ryan C. Fields, M.D., the Kim and Tim Eberlein Distinguished Professor and chief of the Section of Surgical Oncology in the Department of Surgery and William Hawkins, M.D., a professor of surgery and chief of the Section of Hepatobiliary-Pancreatic and Gastrointestinal Surgery.